Form 8-K Celldex Therapeutics, For: Apr 16
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/18/2026
- Wall St ends lower for the day and week as chip selloff broadens
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Assassin's Creed Black Flag Resynced sells 3M copies in a week
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Adobe has received a takeover approach by a Big Tech company - Betaville
- Wall St ends lower for the day and week as chip selloff broadens
Cowen Downgrades Celldex Therapeutics (CLDX) to Market Perform
April 16, 2018 1:02 PM EDTCowen downgraded Celldex Therapeutics (NASDAQ: CLDX) from Outperform to Market Perform.
Analyst Boris Peaker commented, "CLDX announced this morning that glemb'a pivotal METRIC study in gpNMB+ TNBC failed to meet its primary PFS endpoint. All glembatumumab development, including checkpoint inhibitor combination in melanoma, will... More
Celldex Therapeutics (CLDX) PT Lowered to $2.50 at H.C. Wainwright
April 16, 2018 10:54 AM EDTH.C. Wainwright lowered its price target on Celldex Therapeutics (NASDAQ: CLDX) to $2.50 (from $10.00) while maintaining a Buy rating.
Analyst Joseph Pantginis commented, "This morning, Celldex announced that the Phase 2b METRIC Study of glembatumumab vedotin compared to Xeloda in patients with metastatic... More
Celldex (CLDX) Set to Open Lower By 49% After METRIC Study Fails
April 16, 2018 8:24 AM EDTCelldex (NASDAQ: CLDX) was set to open lower by 49% Monday morning after announcing its Phase 2b METRIC Study of glembatumumab vedotin compared to Xeloda in patients with metastatic triple-negative breast cancers that overexpress gpNMB failed to meet its primary endpoint.
... More